Osteoarthritis

IAG is Presenting at Society of Neuro-Oncology Meeting

IAG is Presenting at Society of Neuro-Oncology Meeting

IAG is Presenting at Society of Neuro-Oncology Meeting

IAG team and Julia O’Lynn, IAG’s Director of Bio Innovation and Strategic Partnerships, will be attending the Society of Neuro-Oncology (SNO 2022) 27th Annual Meeting and Educational Day in Tampa, Florida, on November 16 – 20, 2022.

IAG’s team will be meeting with biotech companies and addressing their challenges including trial design, dealing with pseudo-progression, finding optimal endpoints to demonstrate novel therapeutics’ efficacy. We will speak about our platform DYNAMIKA and use of Artificial Intelligence in neuro-oncology trials and explore how IAG’s novel strategies, including advanced imaging biomarkers and AI can support precision medicine and drug development.

Together with our biotech partner CNS Pharmaceuticals Inc., we will be presenting the preliminary results from a  randomized, controlled trial of Berubicin.

Currently, 31 patients are enrolled with 21 in the Berubicin arm and 10 in the Lomustine arm. Trial design: https://clinicaltrials.gov/ct2/show/NCT04762069 The data available shows that Berubicin and Lomustine arms are presently balanced with relatively comparable safety profiles. This study will evaluate the efficacy of this novel drug and potentially provide therapeutic options for patients after first-line therapy.  An updated profile of the patient population, safety, and initial efficacy will be presented.

POSTER INFORMATION

A randomized, controlled trial of Berubicin, a topoisomerase II poison that crosses the blood-brain barrier (BBB), after first-line therapy for glioblastoma multiforme (GBM): Preliminary Results, Authors: S. Silberman, J. O’Lynn, O. Kubassova

If you are not attending and would like to request a poster or to schedule a call: imaging.experts@ia-grp.com

About IAG, Image Analysis Group

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG partners with biotechnology and pharmaceutical companies and applies AI and Precision Medicine to accelerate drug approval.

IAG takes a holistic approach to biotech’s clinical development and brings together:

  • An efficient purpose-built cloud-based system with embedded quality controls for trial data management (DYNAMIKA)
  • Patented methodologies for quantitative assessment of treatment efficacy and safety
  • Expertise in detecting treatment effects including pseudo-progression and pseudo-response
  • Expertise to ensure regulatory compliance, targeted drug development and scientific credibility of your data
  • Ensures that its bio-pharmaceutical clients gain the greatest benefits from early objective decision making on treatment efficacy from utilizing advanced imaging techniques

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

About SNO, the Society for Neuro-Oncology

The Society for Neuro-Oncology exists to advance multi-disciplinary brain tumor research, education, and collaboration to drive discovery and improve patient care. click here.

Learn more: www.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linkedin

News

CEO of IAG Joins Biotech Leaders In the British Parliament, Westminster

Dr Kubassova attends the Global Medical Excellence Awards Dinner and Ceremony.

IAG Successfully Passes ISO13485 Certification Audit

IAG’s solutions follow ISO13485 21 CFR part 11 quality standards.

IAG & Collaborators Present the Latest Data at ACR 2023 #PsA #SSc #OA

IAG’s team will present new data from musculoskeletal research studies.

IAG’s will Attend Jefferies London Healthcare

Join us at Jefferies London Healthcare Conference, 14-16 November 2023.

Events

Meet IAG’s Team at EULAR 2022, Copenhagen

Meet IAG’s Team at EULAR 2022, Copenhagen

Meet IAG’s Team at EULAR 2022, Copenhagen

Dr. Olga Kubassova, IAG’s CEO, will be attending the European Congress of Rheumatology (EULAR 2022) in in Copenhagen, on June 1 – 4, 2022.

IAG’s team will be meeting with key biotech companies and addressing the challenges they face in pharmaceutical trials to explore IAG’s novel strategies, including advanced imaging biomarkers and Artificial Intelligence in precision medicine and drug development.

POSTER INFORMATION

Use of Artificial Intelligence and cloud-based infrastructure to improve the speed and accuracy of eligibility reads in osteoarthritis trials. POS1127

M. Boesen, C. Pereira da Costa, J. O’Lynn, A. Patterson, D. Kessler, O. Kubassova

If you are not attending, schedule a call: imaging.experts@ia-grp.com

IAG partners with biotechnology and pharmaceutical companies and applies AI and Precision Medicine to accelerate drug approval.

IAG takes a holistic approach to biotech’s clinical development and brings together:

  • An efficient purpose-built cloud-based system with embedded quality controls for trial data management (DYNAMIKA)
  • Patented methodologies for quantitative assessment of treatment efficacy and safety
  • Expertise in detecting treatment effects including pseudo-progression and pseudo-response
  • Expertise to ensure regulatory compliance, targeted drug development and scientific credibility of your data
  • Ensures that its bio-pharmaceutical clients gain the greatest benefits from early objective decision making on treatment efficacy from utilizing advanced imaging techniques

Discover our risk assessment and management strategies to overcome the challenges in your trial by contacting IAG at imaging.experts@ia-grp.com

About EULAR

European Congress of Rheumatology (EULAR 2022) is one of the the most prestigious meetings in the world for rheumatology providing a forum of an unparalleled opportunity to the highest standard for scientific, both clinical and basic, educational and social exchange between professionals.

To find out more about this conference click here.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more: www.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linkedin

News

CEO of IAG Joins Biotech Leaders In the British Parliament, Westminster

Dr Kubassova attends the Global Medical Excellence Awards Dinner and Ceremony.

IAG Successfully Passes ISO13485 Certification Audit

IAG’s solutions follow ISO13485 21 CFR part 11 quality standards.

IAG & Collaborators Present the Latest Data at ACR 2023 #PsA #SSc #OA

IAG’s team will present new data from musculoskeletal research studies.

IAG’s will Attend Jefferies London Healthcare

Join us at Jefferies London Healthcare Conference, 14-16 November 2023.

Events

MIMEDX and IAG Partner to Support Knee Osteoarthritis Ph 3 Clinical Trial Program

MIMEDX and IAG Partner to Support Knee Osteoarthritis Ph 3 Clinical Trial Program

Image Analysis Group to Partner with MIMEDX in Support of MIMEDX’s Knee Osteoarthritis Clinical Trial Program

Image Analysis Group to Provide Imaging Strategy and Advanced Imaging Analytics in Support of MIMEDX’s Knee Osteoarthritis Clinical Trial Program

MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts and IAG, Image Analysis Group, a strategic bio-pharma imaging expert announce a partnership in the development of MIMEDX’s mdHACM.

The IAG team has significant experience in using medical imaging to support drug development.

‘We have significant evidence that mdHACM injected into the knees of people with OA provides lasting pain relief and improves function, and we believe it has potential as a DMOAD. MIMEDX has discovered how to preserve the remarkable healing properties of placental membranes when we produce mdHACM, and we have demonstrated that it contains many proteins that influence the biology of cartilage-forming cells and reduce inflammation. We believe these active proteins contribute to the striking, long-lasting benefits we have seen in patients receiving a single injection of mdHACM into their osteoarthritic knee. Following an extensive review and selection process, we are very excited to have world-class partners who are at the forefront of advancing meaningful medicines; working in collaboration accelerates our ability to gather quality data for our future Biologics License Application (BLA), and our potential to bring tremendous benefit for people living with OA.’ said Dr Robert B. Stein, M.D., Ph.D., MIMEDX President, Regenerative Medicine & Biologics Innovation.

About Image Analysis Group (IAG):

IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. www.ia-grp.com

About MIMEDX: 

MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments.

For more information, please reach out to: imaging.experts@ia-grp.com

READ NEXT CASE STUDY >

Supportting Advance Imaging Research in Psoriatic Arthritis Treatment

Supportting Advance Imaging Research in Psoriatic Arthritis Treatment

Academic and Clinical Opinion Leaders and Image Analysis Group Collaborate to Advance Research in Psoriatic Arthritis Treatment.

London, UK — Image Analysis Group (www.ia-grp.com), a pioneer in medical imaging research and analysis, have joined forces in a strategic collaboration with renowned academic and clinical opinion leaders aimed at advancing research in the treatment of Psoriatic Arthritis, study MOSAIC, ClinicalTrials.gov Identifier: NCT03783026.

Amgen, known for its commitment to innovative therapies, recently presented the results of MOSAIC and its clinically relevant research findings on Otezla (Apremilast) in Psoriatic Arthritis during the European League Against Rheumatism (EULAR) 2023 annual meeting. The study, titled “Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients With Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study,” showcased the potential of Apremilast in reducing inflammation, as assessed through MRI scans of the hand.

This work is done in collaboration with MOSAIC study Primary Investigators Prof. Mease and Prof. Ostergaard, number of academic institutions and Image Analysis Group, an organization specializing in advanced medical imaging analysis and research.

This phase 4 trial and collected imaging and clinical data mark a significant step forward in drug developers’ mission to improve the lives of individuals affected by Psoriatic Arthritis. By harnessing the expertise and cutting-edge methodologies and advanced technology platform DYNAMIKA, Image Analysis Group and the collaborators aim to explore and quantify the impact of Apremilast on patients’ lives.

Image Analysis Group’s dedication to developing precise and comprehensive imaging solutions aligns seamlessly with Amgen’s commitment to scientific innovation, said Dr. Olga Kubassova, CEO of IAG.

We are excited to work in this trial with this dedicated group of people, so that our expertise in medical imaging analysis can support understanding and treatment of Psoriatic Arthritis, said Prof. Mikael Boesen, Sn Therapeutic Lead for Musculoskeletal Research at IAG and Head of musculoskeletal imaging and research, Bispebjerg and Frederiksberg Hospital, Radiology, Department of Overlæge, Professor, Bispebjerg and Frederiksberg Hospital, The Parker Institute , Denmark.

This work with Amgen and all collaborators signifies a shared vision of improving patient outcomes through innovation and imaging research.

For media inquiries, interview requests, or further information about this collaboration, please contact

imaging.experts@ia-grp.com

About Image Analysis Group: Image Analysis Group (www.ia-grp.com) is a leading provider of advanced medical imaging research and analysis services. With a focus on precision and scientific rigor, Image Analysis Group collaborates with pharmaceutical companies, research institutions, and healthcare providers to enhance the understanding of diseases and support the development of novel treatments.

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

READ NEXT CASE STUDY >

Supportting Advance Imaging Research in Women’s Reproductive Health

Supportting Advance Imaging Research in Women’s Reproductive Health

Ferring Pharmaceuticals and Image Analysis Group Collaborate to Advance Research in the complex field of pregnancy.

London, UK — Image Analysis Group (www.ia-grp.com), a leader in medical imaging, have joined forces in a strategic collaboration with Ferring Pharmaceuticals to advance Women’s Reproductive Health through AI-driven medical image analysis.

Dr. Philippe Pinton, Senior Vice President, Head of Clinical and Translational Sciences, Global R&D at Ferring Pharmaceuticals, stated, “Our collaboration with IAG is a testament to our commitment to AI-driven research in the complex field of pregnancy.”

Dr. Olga Kubassova, CEO of IAG, added, “We are excited to support the Ferring team in leveraging AI to gain deeper insights into women’s reproductive health, ultimately aiming to enhance the chances of a healthy pregnancy for women globally.”

IAG’s mission is to assist pharmaceutical partners in efficiently developing transformative medicines. This is achieved through their expertise in medical imaging and AI, utilizing their proprietary platform, DYNAMIKA. This platform is designed to efficiently manage large volumes of imaging data in multi-centre trials and incorporates integrated AI modules. The partnership promises innovative approaches to improve women’s health worldwide.

For media inquiries, interview requests, or further information about this collaboration, please contact

imaging.experts@ia-grp.com

About Image Analysis Group: Image Analysis Group (www.ia-grp.com) is a leading advanced medical imaging research and analysis services provider. With a focus on precision and scientific rigour, Image Analysis Group collaborates with pharmaceutical companies, research institutions, and healthcare providers to enhance the understanding of diseases and support the development of novel treatments.

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

READ NEXT CASE STUDY >

University of Leeds partner with IAG to bring a new AI-driven endpoint into clinical trials

University of Leeds partner with IAG to bring a new AI-driven endpoint into clinical trials

DAVIX – DYNAMIKA’s Novel Endpoint for Measuring Proliferation of Neointima

A collaboration between IAG, Image Analysis Group, the University of Leeds, and Prof. Francesco Del Galdo brings a new AI-driven endpoint into clinical trials.

For immediate release: 21 October 2022

Digital Artery Volume Index (DAVIX©) is a novel quantitative MRI-based scoring for the assessment of the blood flow in the arteries.

DAVIX© has been validated as a predictor of the onset of Digital Ulcers in Systemic Sclerosis patients. This innovative methodology is based on the Time-of-Flight Magnetic Resonance Imaging (MRI) angiography and allows to quantitatively assess digital arterial blood flow.

Thus, predicting the onset of Digital Ulcers (DUs) in Systemic Sclerosis (SSc) patients.

The methodology was developed as part of IAG’s DYNAMIKA cloud platform and is now accessible for use in clinical trials and clinical practice for research use. DAVIX© is being deployed by biotech and pharmaceutical companies in global clinical trials as a surrogate outcome measure of SSc vascular disease activity.

This robust methodology can be delivered to clinical sites, with over 100 imaging sites around the world already acquiring the specific MRI data to allow for the assessment of SSc patients with DAVIX©.

“DAVIX© is the first MRI quantitative measure of vascular disease in Systemic Sclerosis. Building on its predictive value for active vascular disease, it is now tested in randomised clinical trials as stratification tool for vascular disease and as a surrogate endpoint for vasoactive interventions,” said Professor Francesco Del Galdo, University of Leeds.

The proprietary name of the endpoint DAVIX© has been copyrighted by the University of Leeds, with a lifetime licence assigned to IAG, Image Analysis Group.

“We look forward to seeing how this unique endpoint will help accelerating the speed of pharmaceutical R&D and most importantly improve therapeutic success for patients,“  said Dr. Olga Kubassova, CEO of IAG, Image Analysis Group.

Neointima proliferation results in vascular wall thickening and gradual loss of luminal patency and is a key pathological feature of Systemic Sclerosis. It is a recognised culprit pathological lesion in Digital Ulcers pulmonary hypertension and renal crisis.

“We are delighted with the results of this collaboration. DAVIX© fits perfectly with IAG’s suite of advanced Artificial Intelligence (AI)-supported imaging methodologies and our strategy to make DYNAMIKA™ the leading image management platform for forward thinking drug developers, “ said Simon Hart, IAG’s Bio-Partnering Director.

“IAG’s has brought technical capabilities and over 15 years of operational experience helping to optimize and standardize DAVIX© in clinical trials. This is a great compliment to all IAG’s teams involved into developing and deploying our Artificial Intelligence methodologies, across hundreds of globally distributed clinical sites, built on our DYNAMIKA™, IAG’s proprietary secure cloud based medical image management and review platform, “ added Prof. Jamshid Dehmeshki, CTO of IAG.  

About IAG, Image Analysis Group

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of DYNAMIKA™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment, and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, and radiological expertise via risk-sharing financing and partnering models.

Learn more: www.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linked In

 

READ NEXT CASE STUDY >